Endocrine Abstracts

Introduction: VIPomas are rare neuroendocrine tumors (NET), usually located in the pancreas that secrete vasoactive intestinal polypeptide (VIP) leading to high-volume watery diarrhea and complications such as hypokalemia, acidosis and dehydration. The management of VIPoma symptoms is often challenging when surgical resection of all the lesions is not feasible. Treatments are then based on somatostatin analogs (SSA) and may also include hepatic chemoembolization, systemic chem...

Objectives: NTRK gene fusions are oncogenic drivers in many solid tumours, including thyroid cancers. In the phase 2 study STARTRK-2 (NCT02568267), entrectinib (a CNS-active tropomyosin receptor kinase [TRK] inhibitor) demonstrated efficacy in patients with NTRK-fp thyroid cancer (objective response rate [ORR]: 40%; clinical cut-off: 31 Oct 2018; n=5). We report updated data from a larger cohort with longer follow-up.Methods: A...

Purpose: Bone metastases (BM) are frequent in differentiated thyroid cancer (DTC). These patients may present skeletal-related events (SRE), the leading cause of DTC-related morbidity. We aimed to evaluate the clinical features, treatment approaches, and outcomes including overall survival (OS) of DTC patients with BM complicated by SRE and their evolution over time.Methods: 178 consecutive DTC patients harbouring BM were enrolled in this retrospective s...

Background: Presence of venous vascular invasion is a criterion of intermediate risk of recurrence in papillary thyroid carcinoma (PTC). However, the presence and type of vascular invasion (lymphatic or venous) is often underreported and its impact on PTCs without other risk features remains unknown.Objective: To evaluate the impact of both lymphatic and venous invasion on the risk of recurrence/persistence on otherwise low-risk PTCs. <p class="abste...

Background: Presence of venous vascular invasion is a criterion of intermediate risk of recurrence in papillary thyroid carcinoma (PTC). However, the presence and type of vascular invasion (lymphatic or venous) is often underreported and its impact on PTCs without other risk features remains unknown.Objective: To evaluate the impact of both lymphatic and venous invasion on the risk of recurrence/persistence on otherwise low-risk PTCs.<p class="abstex...